Recently stock market analysts have updated their consensus ratings on shares of Acorda Therapeutics, Inc. (NASDAQ:ACOR). The latest broker reports which are currently outstanding on Monday 9th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

03/30/2016 – Goldman Sachs began new coverage on Acorda Therapeutics, Inc. giving the company a “sell” rating. They now have a USD 23 price target on the stock.

02/11/2016 – Acorda Therapeutics, Inc. had its “buy” rating reiterated by analysts at Stifel Nicolaus. They now have a USD 53 price target on the stock.

01/19/2016 – Leerink Swann began new coverage on Acorda Therapeutics, Inc. giving the company a “market perform” rating. They now have a USD 35 price target on the stock.

01/06/2016 – Acorda Therapeutics, Inc. had its “buy” rating reiterated by analysts at Aegis Capital. They now have a USD 52 price target on the stock.

10/22/2015 – Acorda Therapeutics, Inc. had its “hold” rating reiterated by analysts at JP Morgan.

10/05/2015 – Acorda Therapeutics, Inc. had its “outperform” rating reiterated by analysts at Cowen. They now have a USD 65 price target on the stock.

08/31/2015 – Raymond James began new coverage on Acorda Therapeutics, Inc. giving the company a “market perform” rating.

07/31/2015 – Acorda Therapeutics, Inc. had its “hold” rating reiterated by analysts at Canaccord Genuity. They now have a USD 32 price target on the stock.

06/22/2015 – Acorda Therapeutics, Inc. had its “buy” rating reiterated by analysts at MLV & Co. They now have a USD 58 price target on the stock.

06/09/2015 – Guggenheim began new coverage on Acorda Therapeutics, Inc. giving the company a “neutral” rating.

05/08/2015 – Acorda Therapeutics, Inc. was upgraded to “buy” by analysts at Zacks. They now have a USD 33 price target on the stock.

04/22/2015 – Piper Jaffray began new coverage on Acorda Therapeutics, Inc. giving the company a “neutral” rating.

02/11/2015 – Acorda Therapeutics, Inc. had its “outperform” rating reiterated by analysts at RBC Capital. They now have a USD 45 price target on the stock.

01/13/2015 – Acorda Therapeutics, Inc. had its “neutral” rating reiterated by analysts at Citigroup. They now have a USD 46 price target on the stock.

10/31/2014 – Acorda Therapeutics, Inc. had its “outperform” rating reiterated by analysts at FBR Capital Markets. They now have a USD 59 price target on the stock.

Acorda Therapeutics, Inc. has a 50 day moving average of 27.31 and a 200 day moving average of 34.58. The stock’s market capitalization is 1.11B, it has a 52-week low of 24.83 and a 52-week high of 43.63.

The share price of the company (NASDAQ:ACOR) was up +1.83% during the last trading session, with a high of 26.22 and the volume of Acorda Therapeutics, Inc. shares traded was 490374.

View other investors thoughts on Acorda Therapeutics, Inc. on our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.